title: Treatment of cytomegalovirus infection after renal transplantation: experience from a single center in China.
abstract: BACKGROUND
  We compared the efficacy and safety of 2 different treatments of CMV infection, including asymptomatic CMV replication and CMV disease.
  
  
  METHODS
  852 renal transplantation recipients, including asymptomatic CMV replication and CMV disease, received antiviral therapies of intravenous acyclovir or comprehensive anti-infection solution, mainly with intravenous ganciclovir. Effect, time, acute allograft rejection, and safety were analyzed during the antiviral therapy
  
  
  RESULTS
  The total effective rates were higher with ganciclovir in both asymptomatic CMV replication (98.96% vs. 84.90%) and CMV disease (96.29% vs. 50.36%). Ganciclovir significantly shortened antiviral therapy duration in both asymptomatic CMV replication (15.0 ± 2.3 days vs. 16.0 ± 3.4 days) and CMV disease (19.7 ± 3.1 days vs. 21.5 ± 4.0 days). The acute allograft rejection incidences were significantly lower with ganciclovir in both asymptomatic CMV replication (8% vs. 14%) and CMV disease (11% vs. 22%). CMV-IEA was detected in renal grafts of patients with acute rejection. There was more CMV-associated acute rejection using acyclovir than using ganciclovir. Except for the higher incidence of anemia leucopenia and anemia with ganciclovir, the safety profiles of both drugs were similar.
  
  
  CONCLUSIONS
  Comprehensive anti-infection solution, mainly with intravenous ganciclovir, can effectively treat CMV infection, shorten duration of therapy, and decrease acute rejection. The few adverse effects had negligible effects on use of ganciclovir.
authors.affiliation: Center of Nephropathy, The First Affiliated Hospital, Medical College, Xi'an Jiaotong University, Xi'an, Shaanxi, PR China. leon4344@126.com
authors.forename: Yang
authors.initials: Y
authors.lastname: Li
authors.forename: Hang
authors.initials: H
authors.lastname: Yan
authors.forename: Wu-Jun
authors.initials: WJ
authors.lastname: Xue
authors.forename: Pu-Xun
authors.initials: PX
authors.lastname: Tian
authors.forename: Xiao-Ming
authors.initials: XM
authors.lastname: Ding
authors.forename: Xiao-Ming
authors.initials: XM
authors.lastname: Pan
authors.forename: Xin-Shun
authors.initials: XS
authors.lastname: Feng
authors.forename: He-Li
authors.initials: HL
authors.lastname: Xiang
authors.forename: Jun
authors.initials: J
authors.lastname: Hou
authors.forename: Xiao-Hui
authors.initials: XH
authors.lastname: Tian
authors.forename: Jin
authors.initials: J
authors.lastname: Zheng
authors.forename: Chen-Guang
authors.initials: CG
authors.lastname: Ding
authors.forename: Ping
authors.initials: P
authors.lastname: Fan
authors.forename: Hong-Bao
authors.initials: HB
authors.lastname: Liu
mesh_terms: D000212:Acyclovir / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002681:China; D003587:Cytomegalovirus / Q000187:drug effects / Q000472:pathogenicity / Q000502:physiology; D003586:Cytomegalovirus Infections / Q000188:drug therapy* / Q000209:etiology* / Q000821:virology; D004279:DNA, Viral / Q000097:blood; D005260:Female; D015774:Ganciclovir / Q000009:adverse effects / Q000627:therapeutic use*; D006084:Graft Rejection / Q000517:prevention & control / Q000821:virology; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016896:Treatment Outcome; D014779:Virus Replication / Q000187:drug effects
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D015774:Ganciclovir; D000212:Acyclovir